[Synthetic lethality as a new concept for the treatment of cancer]

Area of Science:

• Molecular Biology
• Cancer Genetics
• Therapeutics

Background:

• DNA damage triggers a DNA-damage-response (DDR) network for cell cycle arrest, DNA repair, or apoptosis.
• Mutations in DDR genes are common in cancer, potentially causing a 'mutator-phenotype' driving proliferation.
• These DDR gene alterations represent tumor-specific vulnerabilities exploitable for cancer treatment.

Purpose of the Study:

• To discuss the therapeutic concept of synthetic lethality.
• To highlight clinical applications of synthetic lethality in treating various cancers.
• To review emerging synthetic lethality-based strategies nearing clinical evaluation.

Main Methods:

• Review of existing literature on DNA-damage-response (DDR) pathways.
• Analysis of clinical trial data for synthetic lethality-based cancer therapies.
• Survey of preclinical and early-stage clinical studies of novel synthetic lethality approaches.

Main Results:

• Synthetic lethality has demonstrated successful clinical applications in treating specific cancer types.
• Several novel synthetic lethality-based therapeutic strategies are advancing towards clinical testing.
• The 'Achilles heel' of cancer, represented by DDR gene mutations, is being effectively targeted.

Conclusions:

• Synthetic lethality represents a promising, genetically-guided therapeutic strategy for cancer treatment.
• Exploiting tumor-specific vulnerabilities arising from DDR gene mutations offers targeted treatment options.
• Continued development of synthetic lethality approaches holds significant potential for future cancer therapies.